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ABSTRACT 
Olfactory neuroblastoma, also known as esthesioneuroblastoma (ENB), is a rare 
malignant tumour of the basal layer of the olfactory epithelium, which originally 
develops unilaterally, accounting for 3-6% of all intranasal tumours. We present the 
case of a patient with a voluminous ethmoidal lesion that invaded the left basal 
frontal lobe and left orbit. The biopsy revealed a stage C KADISH, grade III 
neuroblastoma. The patient followed a multimodal treatment with chemotherapy 
and radiation therapy to which he responded partially, then returned after 11 months 
for sphincter disorder and bilateral sciatic type pain. An MRI showed metastasis of 
the filum terminale, the anatomopathological exam identifying also neuroblastoma. 
CT and MRI imaging are required for a correct assessment of the regional extension 
of olfactory neuroblastoma, response to oncological treatment but also for the 
detection of secondary lesions found in a small number of cases.  
 
INTRODUCTION 
ENB is a rare malignancy, includes 3% of all intranasal tumours (1), was 
first described in 1924 (2), and it develops from the olfactory epithelium 
of the cribriform plate. These tumours are initially located unilaterally, 
and then invades orbit, nasal fossa, skull base, and intracranial space. 
The risk factors are unknown and there is a bimodal incidence at 10-15 
years and 40-50 years. The most common symptoms are nasal 
congestion, anosmia, epistaxis, headache, and diplopia. These tumours 
have a high potential for regional and distance extension and 
multimodal treatment may help patients and increase their survival 
rate (3). 
 
CASE PRESENTATION 
A 33-year-old patient presented to the emergency room with headache 
and vomiting. CT exploration was recommended which showed 
hydrocephalus and a lesion that occupied the ethmoidal air cells, an 
extension in the nasal fossa, the anterior cranial fossa with bone lysis. 
A gadolinium enhanced MRI was performed that showed a 33/34/23 
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mm (AP/CC/T) lesion, with a heterogeneous 
enhancement, with calcified areas, occupying mostly 
of the nasal fossa and all ethmoid cells, most likely 
developing from the cribriform plate, invading the 
orbit (with mass effect on the internal muscles) and 
frontal lobes, more evident in the left side (Fig. 1, Fig. 
2, Fig. 3, Fig. 4).  
 
 
 
FIGURE 1. Sag T2WI. The tumour occupying the nasal fosa, 
originating from cribriform blade with superior extension. 
 
 
 
FIGURE 2. MRI Cor Gd-T1WI.  
 
 
FIGURE 3. Sag CT (bone window): bone lysis. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4. (A) Axial T2WI-extension of the frontal lobe; (B) Axial 
T2WI - mass effect on the internal muscles in the left orbit. 
 
After the biopsy, the anatomopathological exam 
concluded stage III Kadish group C neuroblastoma. 
In this case the patient followed two chemotherapy 
cycles but abandoned it later because he was known 
to have hepatitis B and the viremia level was 
increasing. Therefore, he continued only with 
radiotherapy.  
The patient returned to control after six months 
when the MRI scan showed a decrease in tumour 
size, with the same characteristics as before, and was 
kept under control for one year. After one year the 
patient came back with bilateral sciatica and major 
sphincter dysfunctions. The MRI exam of lumbar 
region highlighted a hyperintense T1 and T2, 
hypointense STIR lesion in the S1 vertebral body and 
a nodular vivid enhancing lesions of cauda equina in 
S1 and S2 region, suggestive of secondary lesion (Fig. 
5, Fig. 6); the anatomopathological examination 
confirmed the diagnosis of metastasis from 
neuroblastoma.  
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FIGURE 5. MRI Axial STIR - S1 vertebral body level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. S1 secondary lesion (A – T1WI; B – Gd enhanced-T1WI)) 
 
After 10 episodes of lumbar radiotherapy, the 
patient returned accusing headache, diplopia and 
diffuse cervico-lumbar pain. MRI exploration 
revealed a stationary aspect of the tumor compared 
to the previous exam. The patient wanted to be 
discharged and unfortunately, he died shortly 
afterwards. 
 
DISCUSSIONS 
Olfactory neuroblastoma is a tumour which 
originates from the olfactory cells of the cribriform 
blade and, although it develops initially in an 
unilateral manner, it invades afterwards the bilateral 
intracranial spaces. Kadish classifies these tumours 
in three classes (4): A - limited to the nasal cavity, B - 
infiltrated into the nasal cavity and paranasal and C - 
extended beyond the nasal and paranasal cavity. 
Our case was classified in stage C and histologically 
in class III. There are four histological classes that 
divide this type of tumour by histological cellularity 
and histochemical analysis. According to some 
authors, ENB it is most likely congenital, and it 
develops even in intrauterine life (5). 
The role of imaging in the staging of ENB is very 
important. In 40% of cases, it extends in the 
paranasal sinuses, in 30% extension is intracranial, 
and in 30% extension is orbital (6). MRI is the most 
used technique in staging because the report on the 
extension of the tumour in the adjacent tissues can 
be very thorough. 
 Very important are the CECT and PET-CT exams 
of lymph nodes because esthesioneuroblastoma 
disseminates in cervical and laterocervical lymph 
nodes which are asymptomatic and undetectable on 
physical exam. CECT and PET-CT can highlight these 
lymph nodes by marked contrast enhancement on 
CECT and moderate to highly avid of FDG on PET/CT.
 Some studies highlight a cervical dissemination in 
the lymph nodes in 30% of cases and the presence 
of secondary lesions are rare and very rare for spine 
(7). In our case there was secondary involvement of 
vertebral body of S1 and also a metastasis of cauda 
equina in S1 and S2 region. 
 Many studies show that patients treated with 
surgery have a 5-year survival rate of about 50%, 
while surgery combined with chemotherapy prolong 
survival to 65% at 5 years in the case of local 
esthesioneuroblastoma (8,9). 
 In local advanced ENB, resection of the cervical 
lymph nodes is performed to reduce the risk of 
recurrences. Postoperative chemotherapy and 
radiotherapy in patient with lymph nodes metastasis 
have decreased recurrences and the survival rate at 
10 years was 80%. 
 Chemotherapy combined with radiotherapy is 
widely accepted recently, with a survival rate of 35%. 
Despite lymph node resection, radiotherapy and 
chemotherapy, in most cases of advanced ENB 
lymph node recurrence is detected 12 months after 
completion of treatment. 
 Currently, radiotherapy in ENB is used in 
combination with surgery and chemotherapy 
because there are no randomized trials to guide 
radiotherapy treatment, but radiotherapy plays an 
important role in the treatment plan in early stages 
with definitive cure and good tumour control. The 
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doses used are 50-60 Gy with intensity‐modulated 
radiation therapy to minimize doses to the optic 
structures, pituitary gland and brain (10). 
 
CONCLUSIONS 
Olfactory neuroblastoma is a rare tumour that 
originates from olfactory epithelium and extends 
into the orbit, nasal fossa, skull base and intracranial 
space. The combined use of CT and MRI techniques 
is excellent in providing necessary information for 
treatment planning. Recognizing the limitation of 
current data, surgical resection and postoperative 
radiation therapy for resectable lesions is the most 
commonly used management approach. For 
unresectable tumours, radiation alone or 
chemoradiation therapy are also viable treatment 
options. Palliative chemotherapy has not shown a 
clear survival benefit in patients with recurrent 
and/or metastatic disease. 
Considering the metastatic potential of this type 
of tumour, a rigorous imaging examination is 
required for an early diagnosis and a more effective 
treatment. 
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